OVERVIEW
Join us on Tuesday, May 18, 2021, at 8:30 AM EDT for a live web-based CME roundtable discussion with Drs Christopher Cannon and Stephen Rosenson, as they review new data from ACC 2021 related to the use of PCSK9 inhibitors, and other lipid-lowering agents, for the management of patients with dyslipidemia to reduce the risk of future cardiovascular events.
GOAL STATEMENT
The goal of this activity is to improve understanding of new data presented at ACC 2021 related to proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors.
LEARNING OBJECTIVES
Upon completion of this activity, participants will Have increased knowledge regarding the: [LIST] [ITEM]New data related to use of PCSK9 inhibitors presented at ACC 2021 [ITEM]Key insights from ACC 2021 related to dyslipidemia management and cardiovascular (CV) risk reduction[/LIST]
ACCREDITATION STATEMENT
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team [JALOGO] [MEDSCAPE]
[bold]For Physicians[/bold] Medscape, LLC designates this live activity for a maximum of 0.75 [italic]AMA PRA Category 1 Credit(s)™[/italic]. Physicians should claim only the credit commensurate with the extent of their participation in the activity. [bold]For Nurses[/bold] Awarded 0.75 contact hour(s) of nursing continuing professional development for RNs and APNs
Supported by an independent educational grant from [bold]Amgen[/bold].